Tofacitinib in Combination With Conventional Disease‐Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis: Patient‐Reported Outcomes From a Phase III Randomized Controlled Trial

OBJECTIVE: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). We compared patient‐reported outcomes (PROs) in patients with RA treated with tofacitinib or placebo in combination with conventional disease‐modifying antirheumatic drugs (DMARDs). METHODS: In a...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Arthritis Care Res (Hoboken)
Main Authors: Strand, Vibeke, Kremer, Joel M., Gruben, David, Krishnaswami, Sriram, Zwillich, Samuel H., Wallenstein, Gene V.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2017
Assuntos:
Brief Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413813/
https://ncbi.nlm.nih.gov/pubmed/27565000
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/acr.23004
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados